KR20230011967A - 1,4,5,6-테트라하이드로피리미딘-2-아민 유도체 - Google Patents

1,4,5,6-테트라하이드로피리미딘-2-아민 유도체 Download PDF

Info

Publication number
KR20230011967A
KR20230011967A KR1020227042726A KR20227042726A KR20230011967A KR 20230011967 A KR20230011967 A KR 20230011967A KR 1020227042726 A KR1020227042726 A KR 1020227042726A KR 20227042726 A KR20227042726 A KR 20227042726A KR 20230011967 A KR20230011967 A KR 20230011967A
Authority
KR
South Korea
Prior art keywords
group
fluoro
indazole
amino
acetamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227042726A
Other languages
English (en)
Korean (ko)
Inventor
겐이치 고모리
하루카 야마다
하야토 시미즈
야스히로 아가
아유미 오가와
도루 하세가와
다카시 마쓰시타
야스노리 도쿠나가
Original Assignee
유비이 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유비이 가부시키가이샤 filed Critical 유비이 가부시키가이샤
Publication of KR20230011967A publication Critical patent/KR20230011967A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020227042726A 2020-05-14 2021-05-13 1,4,5,6-테트라하이드로피리미딘-2-아민 유도체 Pending KR20230011967A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2020-085420 2020-05-14
JP2020085420 2020-05-14
PCT/JP2021/018252 WO2021230325A1 (ja) 2020-05-14 2021-05-13 １，４，５，６－テトラヒドロピリミジン－２－アミン誘導体

Publications (1)

Publication Number Publication Date
KR20230011967A true KR20230011967A (ko) 2023-01-25

Family

ID=78524455

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227042726A Pending KR20230011967A (ko) 2020-05-14 2021-05-13 1,4,5,6-테트라하이드로피리미딘-2-아민 유도체

Country Status (10)

Country Link
US (1) US20230192661A1 (https=)
EP (1) EP4151632A4 (https=)
JP (1) JP7661969B2 (https=)
KR (1) KR20230011967A (https=)
CN (1) CN115551846B (https=)
AU (1) AU2021270095A1 (https=)
BR (1) BR112022023058A2 (https=)
CA (1) CA3182964A1 (https=)
MX (1) MX2022014200A (https=)
WO (1) WO2021230325A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023085396A1 (ja) * 2021-11-12 2023-05-19 Ｕｂｅ株式会社 アルポート症候群を治療または予防するための医薬組成物
EP4733297A1 (en) * 2023-06-22 2026-04-29 Antibody Therapeutics, Inc. Integrin-inhibiting small molecule compound

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008145A1 (en) 1995-08-30 1997-03-06 G.D. Searle & Co. Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists
WO1999044994A1 (en) 1998-03-04 1999-09-10 G.D. Searle & Co. Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists
WO1999052896A1 (en) 1998-04-10 1999-10-21 G.D. Searle & Co. Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists
WO2000051686A1 (en) 1999-03-04 2000-09-08 G.D. Searle & Co. Use of integrin antagonist and a chemotherapeutic agent in the treatment of neoplasia
WO2004060376A1 (en) 2002-12-20 2004-07-22 Pharmacia Corpration The r-isomer of beta amino acid compounds as integrin receptor antagonists derivatives
WO2014015054A1 (en) 2012-07-18 2014-01-23 Saint Louis University Beta amino acid derivatives as integrin antagonists
US20140051715A1 (en) 2012-07-18 2014-02-20 Saint Louis University 3,5 Phenyl-Substituted Beta Amino Acid Derivatives as Integrin Antagonists
WO2017117538A1 (en) 2015-12-30 2017-07-06 Saint Louis University Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008145A1 (en) 1995-08-30 1997-03-06 G.D. Searle & Co. Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists
WO1999044994A1 (en) 1998-03-04 1999-09-10 G.D. Searle & Co. Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists
WO1999052896A1 (en) 1998-04-10 1999-10-21 G.D. Searle & Co. Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists
WO2000051686A1 (en) 1999-03-04 2000-09-08 G.D. Searle & Co. Use of integrin antagonist and a chemotherapeutic agent in the treatment of neoplasia
WO2004060376A1 (en) 2002-12-20 2004-07-22 Pharmacia Corpration The r-isomer of beta amino acid compounds as integrin receptor antagonists derivatives
WO2014015054A1 (en) 2012-07-18 2014-01-23 Saint Louis University Beta amino acid derivatives as integrin antagonists
US20140051715A1 (en) 2012-07-18 2014-02-20 Saint Louis University 3,5 Phenyl-Substituted Beta Amino Acid Derivatives as Integrin Antagonists
WO2017117538A1 (en) 2015-12-30 2017-07-06 Saint Louis University Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
Angewandte Chemie International Edition in English, 2018, 57(13), 3298-3321.
Biochemical Pharmacology, 2016, 117, 88-96.
Cell, 1999, 96(3), 319-328.
Cell, 2002, 110(6), 673-687.
Cellular and Molecular Life Sciences, 2017, 74(12), 2263-2282.
Clinical & Experimental Metastasis, 2003, 20, 203-213.
Cold Spring Harbor Perspectives in Biology, 2011, 3(11), a005017.
Cold Spring Harbor Perspectives in Biology, 2016, 8(5), a021873.
European Respiratory Journal, 2015, 46(2), 486-494.
Journal of Hepatology, 2008, 48(3), 453-464.
Molecular Aspects of Medicine, 2019, 65, 2-15.
Nature Communications, 2017, 8(1), 1118.
Nature Medicine, 2013, 19(12), 1617-1624.
Nature Reviews Nephrology, 2016, 12(6), 325-338.
Neurobiology of Aging, 2008, 29(10), 1485-1493.
Pharmacology Research and Perspectives, 2017, 5(5), e00354.
Science Translational Medicine, 2015, 7(288), 288ra79.
The American Journal of Pathology, 2003, 163(4), 1261-1273.
The American Journal of Pathology, 2004, 164(4), 1275-1292.

Also Published As

Publication number Publication date
CN115551846B (zh) 2024-03-08
JP7661969B2 (ja) 2025-04-15
EP4151632A4 (en) 2024-04-24
CA3182964A1 (en) 2021-11-18
AU2021270095A1 (en) 2022-12-22
JPWO2021230325A1 (https=) 2021-11-18
EP4151632A1 (en) 2023-03-22
WO2021230325A1 (ja) 2021-11-18
MX2022014200A (es) 2022-12-07
US20230192661A1 (en) 2023-06-22
BR112022023058A2 (pt) 2022-12-20
CN115551846A (zh) 2022-12-30

Similar Documents

Publication Publication Date Title
JP7789886B2 (ja) Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体
JP7767492B2 (ja) Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
CN104066729A (zh) 溶血磷脂酸受体拮抗剂
PT1024138E (pt) Derivados de pirazole
PT2406253E (pt) Derivados de benzofuranilo utilizados como inibidores de glucocinase
US11096931B2 (en) Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
CA2871453A1 (en) Quinazolinedione derivative
JP7661969B2 (ja) １，４，５，６－テトラヒドロピリミジン－２－アミン誘導体
WO2023085396A1 (ja) アルポート症候群を治療または予防するための医薬組成物
KR20130141554A (ko) 신규한 항암제
TW201718548A (zh) 哌嗪（ｐｉｐｅｒａｚｉｎｅ）衍生物
RU2845863C1 (ru) Производное 1,4,5,6-тетрагидропиримидин-2-амина
JP7624745B2 (ja) Ｔｒｐｖ４受容体リガンド
CN111936488A (zh) 用于治疗寄生虫感染的新颖化合物
US9598381B2 (en) SMYD2 inhibitors
JP2009504628A (ja) オキシトシン拮抗薬としての置換トリアゾール誘導体
AU2003221394B2 (en) Novel pyridone derivative
WO2022000071A1 (en) Matrix metalloproteinase inhibitors (mmpis)
NZ751725B2 (en) Pyrazolopyridine derivative having glp-1 receptor agonist effect
KR20180135448A (ko) Kcnq2∼5 채널 활성화제의 결정다형

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902